Tamoxifen for flutamide/finasteride-induced gynecomastia

Urology
V R Staiman, F C Lowe

Abstract

Current therapies for advanced prostate carcinoma lead to a marked decrease in serum testosterone levels, which renders patients impotent. In preliminary studies, combination therapy with flutamide and finasteride has been used as an alternative therapy for the treatment of prostate carcinoma because potency can be preserved. Both of these agents can cause gynecomastia and breast/nipple tenderness. Six men being treated for advanced prostate carcinoma with flutamide/finasteride combination therapy developed painful gynecomastia, which was treated with tamoxifen 10 to 30 mg/day for 1 month. Clinical follow-up included breast measurements and determination of prostate-specific antigen (PSA), testosterone, and estradiol levels. While on this combination therapy for prostate carcinoma, 4 of 6 patients experienced a decrease in PSA level to less than 0.5 ng/mL. All patients remained potent. Serum testosterone increased in each patient who had a baseline level drawn. Estradiol levels were noted to be elevated in 4 of 6 patients at the time of evaluation for gynecomastia. After treatment with tamoxifen, circulating estradiol levels increased in 3 patients from 1.3 to 2.2 times the baseline level. Five patients experienced complete res...Continue Reading

References

Apr 28, 1979·British Medical Journal·D B Jefferys
Aug 1, 1979·The Journal of Clinical Endocrinology and Metabolism·J H MacIndoe
Dec 1, 1977·The Journal of Clinical Endocrinology and Metabolism·L HellmanB Zumoff
Oct 22, 1992·The New England Journal of Medicine·G J GormleyJ S Tenover
Nov 1, 1990·Southern Medical Journal·M T McDermottG S Kidd
Aug 1, 1986·Metabolism: Clinical and Experimental·L N ParkerE R Levin
Mar 1, 1986·International Journal of Radiation Oncology, Biology, Physics·D FassA Tessler
Apr 1, 1981·British Journal of Urology·A S NarayanaD A Culp
Jan 1, 1994·Aesthetic Plastic Surgery·A C Abramo
Jul 15, 1993·The New England Journal of Medicine·S Malozowski
Feb 18, 1993·The New England Journal of Medicine·G D Braunstein

❮ Previous
Next ❯

Citations

Apr 7, 2004·Current Oncology Reports·Allen C Chen, Daniel P Petrylak
May 5, 2005·Current Urology Reports·Allen C Chen, Daniel P Petrylak
Jan 16, 2004·Pharmacology, Biochemistry, and Behavior·Ali Reza Mohajjel Nayebi, Hassan Rezazadeh
Jan 30, 2002·Clinica Chimica Acta; International Journal of Clinical Chemistry·Rachel S Rosenberg ZandEleftherios P Diamandis
May 15, 2002·Fertility and Sterility·Constantine DimitrakakisCarolyn A Bondy
Nov 14, 2002·European Urology·Francesco BoccardoUNKNOWN Italian Prostate Cancer Group
Aug 11, 2000·Critical Reviews in Oncology/hematology·F Boccardo
Sep 21, 2007·The New England Journal of Medicine·Glenn D Braunstein
Jul 10, 2003·Menopause : the Journal of the North American Menopause Society·Constantine DimitrakakisCarolyn Bondy
Mar 17, 2007·International Journal of Clinical Practice·P Gikas, K Mokbel
Dec 6, 2008·Folia Histochemica Et Cytobiologica·Anil K AgrawalEwa Nienartowicz
Jul 5, 2006·Nihon rinsho. Japanese journal of clinical medicine·Hayakazu Nakazawa
Mar 19, 2014·Fertility and Sterility·Cyrus D RahnemaEdward D Kim
May 5, 2009·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·H L Devalia, G T Layer
Dec 3, 2005·The Lancet Oncology·Giuseppe Di LorenzoSabino De Placido
Dec 13, 2005·BJU International·Kevin M O'Connor, John M Fitzpatrick
Feb 23, 2007·BJU International·Martin C NuttallGuy P C Dawkins
Nov 6, 2008·Expert Opinion on Drug Safety·Ari Eckman, Adrian Dobs
May 7, 2016·Andrology·E WibowoR J Wassersug
Dec 8, 2007·Expert Review of Anticancer Therapy·Paul R Sieber
Oct 12, 2005·The Journal of Urology·Adrian Dobs, Malcolm J M Darkes
Mar 26, 2005·Human Reproduction Update·F C H d'Ancona, F M J Debruyne
Sep 10, 2004·The Journal of Clinical Endocrinology and Metabolism·Paul V PlourdePhilippe F Backeljauw
Sep 7, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J ZhouC A Bondy
Mar 15, 2000·The Australasian Journal of Dermatology·M S Wade, R D Sinclair
Sep 1, 2019·Thérapie·Benjamin BatteuxUNKNOWN French National Network of Pharmacovigilance Centres

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.